Jason J Luke, MD
University of Pittsburgh · UPMC Hillman Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jason J Luke, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:27 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06069570 · Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone MetastasesKiromic BioPharma Inc. · recruiting · Carcinoma, Non-Small-Cell Lung Cancer, Bone Metastases From Solid Tumors · principal investigator
- Ph1/Ph2NCT04655157 · Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose IpilimumaJason J. Luke, MD · terminated · Melanoma · principal investigator
- Ph2NCT04056910 · Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant TumorsJason J. Luke, MD · completed · Advanced Solid Tumor, IDH1 Mutation, Glioma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:27 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.